[HTML][HTML] 30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal peptides on drug-naïve women with …
A Schiapaccassa, PA Maranhão… - Diabetology & Metabolic …, 2019 - Springer
Background Obesity is the main risk factor for diabetes and excessive visceral fat triggers
low-grade inflammatory process, mediated by activation and release of cytokines and high …
low-grade inflammatory process, mediated by activation and release of cytokines and high …
[HTML][HTML] The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero …
N Kitao, H Miyoshi, T Furumoto, K Ono… - Cardiovascular …, 2017 - Springer
Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors may have protective effects
in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects …
in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects …
[HTML][HTML] Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
Background Diabetic patients present with an accelerated atherosclerotic process and an
increased risk for future cardiovascular events. In addition to the risk imposed by the disease …
increased risk for future cardiovascular events. In addition to the risk imposed by the disease …
[HTML][HTML] Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus
Background This uncontrolled open label study evaluated the effect of dipeptidyl peptidase-
4 inhibitors (DPP-4i): sitagliptin and vildagliptin on augmentation index standardized for 75 …
4 inhibitors (DPP-4i): sitagliptin and vildagliptin on augmentation index standardized for 75 …
Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: a randomized controlled trial
LN Cosenso-Martin, LT Giollo-Júnior, LAB Fernandes… - Acta …, 2018 - Springer
Aims Several trials have reported that dipeptidyl peptidase-4 (DPP-4) inhibitors, used to treat
type 2 diabetes (T2DM), improve endothelial function. The current study investigated the …
type 2 diabetes (T2DM), improve endothelial function. The current study investigated the …
Vildagliptin, a DPP-4 inhibitor, attenuates endothelial dysfunction and atherogenesis in nondiabetic apolipoprotein E-deficient mice
K Aini, D Fukuda, K Tanaka, Y Higashikuni… - International heart …, 2019 - jstage.jst.go.jp
Summary Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel antidiabetic agents with
possible vascular protection effects. Endothelial dysfunction is an initiation step in …
possible vascular protection effects. Endothelial dysfunction is an initiation step in …
Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis
T Matsui, Y Nishino, M Takeuchi, S Yamagishi - Pharmacological Research, 2011 - Elsevier
Vildagliptin is a stable inhibitor of dipeptidyl peptidase-IV, a responsible enzyme that mainly
inactivates glucagon-like peptide-1, and now one of the widely used agents for the treatment …
inactivates glucagon-like peptide-1, and now one of the widely used agents for the treatment …
Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats
D de Lima Ávila, GR de Araújo, M Silva… - Archives of Medical …, 2013 - Elsevier
BACKGROUND AND AIMS: It is believed that oxidative stress plays a role in the
pathogenesis of diabetes mellitus. Several strategies have been developed with the …
pathogenesis of diabetes mellitus. Several strategies have been developed with the …
Vildagliptin reduces plasma stromal cell‐derived factor‐1α in patients with type 2 diabetes compared with glimepiride
Abstract Aims/Introduction Dipeptidyl peptidase‐4 inhibitors might have pleiotropic
protective effects on cardiovascular disease (CVD), in contrast to sulfonylureas. Therefore …
protective effects on cardiovascular disease (CVD), in contrast to sulfonylureas. Therefore …
Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects
SP Ayalasomayajula, K Dole, YL He… - … medical research and …, 2007 - Taylor & Francis
Background: Vildagliptin is an orally active, potent and selective inhibitor of dipeptidyl
peptidase IV (DPP-4), the enzyme responsible for the degradation of incretin hormones. By …
peptidase IV (DPP-4), the enzyme responsible for the degradation of incretin hormones. By …